Biopharmaceutical company Gilead Sciences reported total revenues of approximately 27.1 billion U.S. dollars in 2023, almost the same amount like in the preceding two years. Product sales accounted for nearly all of the company’s total worldwide revenues.
Gilead’s HIV product portfolio Gilead Sciences announced total product sales of around 27 billion U.S. dollars in 2023, of which around 60 percent were derived from its HIV division. Sales of its top HIV treatment Biktarvy generated 11.9 billion U.S. dollars in the same year. The company continues to grow its HIV division, but there were also year-on-year sales declines for two of its top products: Genvoya and Odefsey. Gilead cannot become too reliant on its HIV division and is looking to develop new products and repurpose existing products for new indications.
Curing the COVID-19 pandemic Drug repurposing is the process of exploring existing treatments to discover new therapeutic benefits. In the race to develop an effective treatment for COVID-19, one potential medication that has gained attention was remdesivir. Originally developed by Gilead Sciences for use against Ebola, clinical trials have shown remdesivir’s safety and efficacy in certain groups of COVID-19 patients. Especially before vaccines became available, the spotlight was on Gilead: it has seen a huge change in its market capitalization.
The net income of Gilead Sciences with headquarters in the United States amounted to 5.6 billion U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total increase by approximately 249 million U.S. dollars. The trend from 2019 to 2023 shows, however, that this increase did not happen continuously.
This statistic shows the top products of biopharmaceutical company Gilead Sciences from 2021 to 2023, based on revenue. Gilead Sciences Inc. is headquartered in California and is specialized in discovering, developing and commercializing therapeutics. In 2023, Gilead Sciences' COVID-19 treatment Veklury (remdesivir) generated some 2.2 billion U.S. dollars in revenue, a significant decrease compared to 5.6 billion in 2021.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Context
The dataset presents median income data over a decade or more for males and females categorized by Total, Full-Time Year-Round (FT), and Part-Time (PT) employment in Gilead town. It showcases annual income, providing insights into gender-specific income distributions and the disparities between full-time and part-time work. The dataset can be utilized to gain insights into gender-based pay disparity trends and explore the variations in income for male and female individuals.
Key observations: Insights from 2023
Based on our analysis ACS 2019-2023 5-Year Estimates, we present the following observations: - All workers, aged 15 years and older: In Gilead town, the median income for all workers aged 15 years and older, regardless of work hours, was $41,667 for males and $33,125 for females.
These income figures indicate a substantial gender-based pay disparity, showcasing a gap of approximately 21% between the median incomes of males and females in Gilead town. With women, regardless of work hours, earning 79 cents to each dollar earned by men, this income disparity reveals a concerning trend toward wage inequality that demands attention in thetown of Gilead town.
- Full-time workers, aged 15 years and older: In Gilead town, among full-time, year-round workers aged 15 years and older, males earned a median income of $49,464, while females earned $64,375Surprisingly, within the subset of full-time workers, women earn a higher income than men, earning 1.3 dollars for every dollar earned by men. This suggests that within full-time roles, womens median incomes significantly surpass mens, contrary to broader workforce trends.
When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2019-2023 5-Year Estimates. All incomes have been adjusting for inflation and are presented in 2023-inflation-adjusted dollars.
Gender classifications include:
Employment type classifications include:
Variables / Data Columns
Good to know
Margin of Error
Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.
Custom data
If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.
Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.
This dataset is a part of the main dataset for Gilead town median household income by race. You can refer the same here
The operating profit of Gilead Sciences with headquarters in the United States amounted to 7.6 billion U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total increase by approximately 3.31 billion U.S. dollars. The trend from 2019 to 2023 shows, however, that this increase did not happen continuously.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Context
The dataset presents the detailed breakdown of the count of individuals within distinct income brackets, categorizing them by gender (men and women) and employment type - full-time (FT) and part-time (PT), offering valuable insights into the diverse income landscapes within Gilead town. The dataset can be utilized to gain insights into gender-based income distribution within the Gilead town population, aiding in data analysis and decision-making..
Key observations
When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2019-2023 5-Year Estimates.
Income brackets:
Variables / Data Columns
Employment type classifications include:
Good to know
Margin of Error
Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.
Custom data
If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.
Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.
This dataset is a part of the main dataset for Gilead town median household income by race. You can refer the same here
The total assets of Gilead Sciences with headquarters in the United States amounted to 62.12 billion U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total increase by approximately 0.49 billion U.S. dollars. The trend from 2019 to 2023 shows, however, that this increase did not happen continuously.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Context
The dataset presents the distribution of median household income among distinct age brackets of householders in Mount Gilead. Based on the latest 2018-2022 5-Year Estimates from the American Community Survey, it displays how income varies among householders of different ages in Mount Gilead. It showcases how household incomes typically rise as the head of the household gets older. The dataset can be utilized to gain insights into age-based household income trends and explore the variations in incomes across households.
Key observations: Insights from 2022
In terms of income distribution across age cohorts, in Mount Gilead, where there exist only two delineated age groups, the median household income is $69,836 for householders within the 45 to 64 years age group, compared to $37,814 for the 65 years and over age group.
When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2018-2022 5-Year Estimates. All incomes have been adjusting for inflation and are presented in 2023-inflation-adjusted dollars.
Age groups classifications include:
Variables / Data Columns
Good to know
Margin of Error
Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.
Custom data
If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.
Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.
This dataset is a part of the main dataset for Mount Gilead median household income by age. You can refer the same here
The net cash of Gilead Sciences with headquarters in the United States amounted to 8.01 billion U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total decrease by approximately 1.13 billion U.S. dollars. The trend from 2019 to 2023 shows, however, that this decrease did not happen continuously.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Context
The dataset tabulates the Gilead township household income by gender. The dataset can be utilized to understand the gender-based income distribution of Gilead township income.
The dataset will have the following datasets when applicable
Please note: The 2020 1-Year ACS estimates data was not reported by the Census Bureau due to the impact on survey collection and analysis caused by COVID-19. Consequently, median household income data for 2020 is unavailable for large cities (population 65,000 and above).
Good to know
Margin of Error
Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.
Custom data
If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.
Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.
Explore our comprehensive data analysis and visual representations for a deeper understanding of Gilead township income distribution by gender. You can refer the same here
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Context
The dataset presents the detailed breakdown of the count of individuals within distinct income brackets, categorizing them by gender (men and women) and employment type - full-time (FT) and part-time (PT), offering valuable insights into the diverse income landscapes within Gilead township. The dataset can be utilized to gain insights into gender-based income distribution within the Gilead township population, aiding in data analysis and decision-making..
Key observations
When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2019-2023 5-Year Estimates.
Income brackets:
Variables / Data Columns
Employment type classifications include:
Good to know
Margin of Error
Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.
Custom data
If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.
Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.
This dataset is a part of the main dataset for Gilead township median household income by race. You can refer the same here
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Context
The dataset presents median income data over a decade or more for males and females categorized by Total, Full-Time Year-Round (FT), and Part-Time (PT) employment in Mount Gilead. It showcases annual income, providing insights into gender-specific income distributions and the disparities between full-time and part-time work. The dataset can be utilized to gain insights into gender-based pay disparity trends and explore the variations in income for male and female individuals.
Key observations: Insights from 2023
Based on our analysis ACS 2019-2023 5-Year Estimates, we present the following observations: - All workers, aged 15 years and older: In Mount Gilead, the median income for all workers aged 15 years and older, regardless of work hours, was $32,768 for males and $24,224 for females.
These income figures indicate a substantial gender-based pay disparity, showcasing a gap of approximately 26% between the median incomes of males and females in Mount Gilead. With women, regardless of work hours, earning 74 cents to each dollar earned by men, this income disparity reveals a concerning trend toward wage inequality that demands attention in thetown of Mount Gilead.
- Full-time workers, aged 15 years and older: In Mount Gilead, among full-time, year-round workers aged 15 years and older, males earned a median income of $43,713, while females earned $47,604Surprisingly, within the subset of full-time workers, women earn a higher income than men, earning 1.09 dollars for every dollar earned by men. This suggests that within full-time roles, womens median incomes significantly surpass mens, contrary to broader workforce trends.
When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2019-2023 5-Year Estimates. All incomes have been adjusting for inflation and are presented in 2023-inflation-adjusted dollars.
Gender classifications include:
Employment type classifications include:
Variables / Data Columns
Good to know
Margin of Error
Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.
Custom data
If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.
Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.
This dataset is a part of the main dataset for Mount Gilead median household income by race. You can refer the same here
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Context
The dataset tabulates the Mount Gilead household income by age. The dataset can be utilized to understand the age-based income distribution of Mount Gilead income.
The dataset will have the following datasets when applicable
Please note: The 2020 1-Year ACS estimates data was not reported by the Census Bureau due to the impact on survey collection and analysis caused by COVID-19. Consequently, median household income data for 2020 is unavailable for large cities (population 65,000 and above).
Good to know
Margin of Error
Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.
Custom data
If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.
Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.
Explore our comprehensive data analysis and visual representations for a deeper understanding of Mount Gilead income distribution by age. You can refer the same here
Gilead Sciences spent some five billion U.S. dollars on research and development in 2023. The statistic illustrates Gilead Sciences' spending on research and development from 2008 to 2023. In 2023, Gilead Sciences shot to the public limelight over its drug remdesivir (brand name Veklury), which was trialed and later approved as a drug against COVID-19.
This statistic displays the projected 2022 revenue for selected top drugs approved in the U.S. in 2018. Biktarvy, developed by Gilead Sciences, is estimated to generate some five billion U.S. dollars in annual revenue in 2024.
https://www.datainsightsmarket.com/privacy-policyhttps://www.datainsightsmarket.com/privacy-policy
The Non-Alcoholic Fatty Liver Disease (NAFLD) market is experiencing robust growth, projected to reach $21.36 billion in 2025 and exhibiting a Compound Annual Growth Rate (CAGR) of 9.56% from 2025 to 2033. This expansion is driven by several factors. The rising prevalence of obesity, type 2 diabetes, and metabolic syndrome—key risk factors for NAFLD—is a major contributor. Increased awareness of NAFLD and improved diagnostic capabilities are leading to earlier detection and treatment, further fueling market growth. Furthermore, the pipeline of innovative therapies, including advancements in anti-fibrotic agents, FXR receptor agonists, and novel drug classes, promises significant therapeutic advancements and market expansion. The market segmentation reveals strong growth across various drug classes, with antioxidants, lipid-lowering agents, and biguanides representing substantial segments. Distribution channels are also diversifying, with online pharmacies gaining traction alongside traditional hospital and retail pharmacies. The geographical distribution indicates significant market potential across North America, Europe, and the Asia-Pacific region, driven by high prevalence rates and increasing healthcare expenditure in these areas. Competition is fierce, with major pharmaceutical companies like AbbVie, Novartis, and Gilead Sciences actively involved in research and development and commercialization efforts. The forecast period (2025-2033) is expected to witness continued market expansion, fueled by ongoing research and development, increased diagnostic capabilities, and an aging global population. However, challenges remain, including the need for more effective and targeted treatments, the high cost of medications, and the lack of widespread awareness in certain regions. Overcoming these hurdles will be crucial for sustainable market growth. The market's success will hinge on the development of novel therapies addressing unmet medical needs, coupled with effective public health initiatives to raise awareness and encourage early diagnosis and management of NAFLD. The diverse range of therapeutic options, combined with the significant unmet clinical need, positions the NAFLD market for substantial long-term growth and innovation. This comprehensive report provides an in-depth analysis of the Non-Alcoholic Fatty Liver Disease (NAFLD) market, offering valuable insights for stakeholders across the pharmaceutical and healthcare industries. With a focus on the period 2019-2033, including a base year of 2025 and a forecast period of 2025-2033, this study meticulously examines market dynamics, growth drivers, and potential challenges. The report covers a projected market value in the billions, offering granular segmentation analysis and strategic recommendations for success in this rapidly evolving market. Recent developments include: June 2024: Eli Lilly and Company presented positive results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, at the European Association for the Study of the Liver (EASL) Congress 2024 to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis.March 2024: Ionis Pharmaceuticals Inc. reported positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor with both doses (120 mg and 90 mg) in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).. Key drivers for this market are: Increasing Burden of Non-alcoholic Fatty Liver Disease, Rising Global Prevalence of Diabetic and Obese Populations; Increasing Awareness about NAFLD. Potential restraints include: Increasing Burden of Non-alcoholic Fatty Liver Disease, Rising Global Prevalence of Diabetic and Obese Populations; Increasing Awareness about NAFLD. Notable trends are: The Fibrosis Treatment Agents Segment is Expected to Witness Significant Growth During the Forecast Period.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Context
The dataset presents median income data over a decade or more for males and females categorized by Total, Full-Time Year-Round (FT), and Part-Time (PT) employment in Gilead township. It showcases annual income, providing insights into gender-specific income distributions and the disparities between full-time and part-time work. The dataset can be utilized to gain insights into gender-based pay disparity trends and explore the variations in income for male and female individuals.
Key observations: Insights from 2023
Based on our analysis ACS 2019-2023 5-Year Estimates, we present the following observations: - All workers, aged 15 years and older: In Gilead township, the median income for all workers aged 15 years and older, regardless of work hours, was $44,844 for males and $31,597 for females.
These income figures indicate a substantial gender-based pay disparity, showcasing a gap of approximately 30% between the median incomes of males and females in Gilead township. With women, regardless of work hours, earning 70 cents to each dollar earned by men, this income disparity reveals a concerning trend toward wage inequality that demands attention in thetownship of Gilead township.
- Full-time workers, aged 15 years and older: In Gilead township, among full-time, year-round workers aged 15 years and older, males earned a median income of $51,771, while females earned $47,500, resulting in a 8% gender pay gap among full-time workers. This illustrates that women earn 92 cents for each dollar earned by men in full-time positions. While this gap shows a trend where women are inching closer to wage parity with men, it also exhibits a noticeable income difference for women working full-time in the township of Gilead township.Interestingly, when analyzing income across all roles, including non-full-time employment, the gender pay gap percentage was higher for women compared to men. It appears that full-time employment presents a more favorable income scenario for women compared to other employment patterns in Gilead township.
When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2019-2023 5-Year Estimates. All incomes have been adjusting for inflation and are presented in 2023-inflation-adjusted dollars.
Gender classifications include:
Employment type classifications include:
Variables / Data Columns
Good to know
Margin of Error
Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.
Custom data
If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.
Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.
This dataset is a part of the main dataset for Gilead township median household income by race. You can refer the same here
Globally, over many years, one of the top drugs for the treatment of HIV/AIDS is Genvoya, marketed by Gilead. In 2023, Genvoya generated some two billion U.S. dollars in revenue. Biktarvy, also marketed by Gilead, was the best-selling HIV/AIDS treatment and generated around 11.9 billion U.S. dollars in revenue. Gilead is the drug manufacturer most specialized in developing drugs for the treatment of HIV/AIDS.
HIV/AIDS cases worldwide
HIV is a virus that attacks the immune system, leading to an increased risk of infections and can lead to death. HIV/AIDS first appeared in global populations in the 1980s. According to current estimates, the prevalence of HIV is highest in low and middle income countries. Eswatini, followed by Lesotho, had the highest rates of HIV infections in 2022. The number of new HIV infections by world region is highest among residents of Eastern and Southern Africa.
Access to HIV/AIDS treatment
Effective treatment for HIV was not available until the early 1990s. Access to therapy has increased since the early 2000s, and as of 2022 there were approximately 30 million people that had access to antiretroviral therapy. Among countries around the world, Uganda, India and Kenya, to name a few, have the lowest rates of access to antiretroviral medications for the treatment of HIV/AIDS. Meanwhile, trends indicate that children living with HIV in Asia or the Pacific have some of the highest rates of access to antiretroviral therapy globally.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Context
The dataset tabulates the Mount Gilead household income by gender. The dataset can be utilized to understand the gender-based income distribution of Mount Gilead income.
The dataset will have the following datasets when applicable
Please note: The 2020 1-Year ACS estimates data was not reported by the Census Bureau due to the impact on survey collection and analysis caused by COVID-19. Consequently, median household income data for 2020 is unavailable for large cities (population 65,000 and above).
Good to know
Margin of Error
Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.
Custom data
If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.
Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.
Explore our comprehensive data analysis and visual representations for a deeper understanding of Mount Gilead income distribution by gender. You can refer the same here
By 2024, Yescarta, a Car-T therapy from Gilead Sciences, is expected to have the largest revenue in both regions with 966 million U.S. dollars in the United States and 321 million U.S. dollars in Europe. This statistic shows the estimated 2024 revenues for selected anti-CD19 Car-T therapy in the U.S. and in Europe.
Biopharmaceutical company Gilead Sciences reported total revenues of approximately 27.1 billion U.S. dollars in 2023, almost the same amount like in the preceding two years. Product sales accounted for nearly all of the company’s total worldwide revenues.
Gilead’s HIV product portfolio Gilead Sciences announced total product sales of around 27 billion U.S. dollars in 2023, of which around 60 percent were derived from its HIV division. Sales of its top HIV treatment Biktarvy generated 11.9 billion U.S. dollars in the same year. The company continues to grow its HIV division, but there were also year-on-year sales declines for two of its top products: Genvoya and Odefsey. Gilead cannot become too reliant on its HIV division and is looking to develop new products and repurpose existing products for new indications.
Curing the COVID-19 pandemic Drug repurposing is the process of exploring existing treatments to discover new therapeutic benefits. In the race to develop an effective treatment for COVID-19, one potential medication that has gained attention was remdesivir. Originally developed by Gilead Sciences for use against Ebola, clinical trials have shown remdesivir’s safety and efficacy in certain groups of COVID-19 patients. Especially before vaccines became available, the spotlight was on Gilead: it has seen a huge change in its market capitalization.